Last week, members of the Taysha team attended the International Rett Syndrome Foundation’s ASCEND 2024 Rett Syndrome National Summit! After connecting with families, community advocates, and the leading clinicians and scientists in #Rettsyndrome, we left #IRSF2024 feeling inspired by the research and advancements in the Rett space. We are grateful for IRSF’s continued support as we work together with the Rett community to investigate a potential #genetherapy for Rett syndrome.
Taysha Gene Therapies
Biotechnology
Dallas, TX 17,707 followers
Taysha Gene Therapies is focused on advancing AAV-based gene therapies for severe monogenic diseases of the CNS.
About us
Taysha Gene Therapies is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. Its lead clinical program TSHA-102 is in development for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. With a singular focus on developing transformative medicines, Taysha aims to address severe unmet medical needs and dramatically improve the lives of patients and their caregivers. The Company’s management team has proven experience in gene therapy development and commercialization. Taysha leverages this experience, its manufacturing process and a clinically and commercially proven AAV9 capsid in an effort to rapidly translate treatments from bench to bedside.
- Website
-
http://www.tayshagtx.com
External link for Taysha Gene Therapies
- Industry
- Biotechnology
- Company size
- 51-200 employees
- Headquarters
- Dallas, TX
- Type
- Public Company
- Founded
- 2020
- Specialties
- Gene Therapy, Central Nervous System, and Molecular Biology
Locations
-
Primary
Get directions
Dallas, TX, US
Employees at Taysha Gene Therapies
Updates
-
Today, we announced positive longer-term clinical data from the low dose cohort of our ongoing REVEAL Phase 1/2 adolescent and adult trial as well as initial clinical data from our REVEAL Phase 1/2 pediatric trial evaluating TSHA-102 in #Rettsyndrome. Tune in to our webcast today at 8:00 a.m. ET to discuss the clinical data. Read the press release and register for the webcast: https://lnkd.in/egEVTtVG
-
-
We will be hosting a live webcast on June 18 to discuss new clinical data from the REVEAL Phase 1/2 adolescent and adult trial and the REVEAL Phase 1/2 pediatric trial evaluating TSHA-102 in #Rettsyndrome. The data will also be presented at the 2024 International Rett Syndrome Foundation (IRSF) Rett Syndrome Scientific Meeting from June 18-19. Register for the webcast and learn more: https://lnkd.in/eVqnnir7
-
-
Today we celebrate Clinical Trials Day, a day to recognize and reflect on the learnings, progress and medical developments that have resulted from clinical trials around the world. We’d like to thank the individuals and families who participate in clinical trials, as well as those who lead and analyze the clinical research. Your efforts and involvement have drastically improved the lives of many and have helped pave the way for the future development of new medicines. #CTD2024 #ClinicalTrialsDay #ClinicaTrials
-
-
Today, we announced our first quarter 2024 earnings and provided an update on our TSHA-102 #genetherapy program in clinical evaluation for #Rettsyndrome. Read the release to learn more about the recent progress we have made to advance TSHA-102: https://lnkd.in/e3dwYMpS
-
-
We’re thrilled to share the recent promotion of Meredith Schultz, MD, MS to Chief Medical Officer and Rumana Haque-Ahmed to Chief Regulatory Officer. Dr. Schultz and Ms. Haque-Ahmed have been instrumental in the development of our TSHA-102 program in clinical evaluation for #Rettsyndrome, and we look forward to their continued leadership as we work toward our mission. Congratulations on your well-deserved new roles! Learn more about our team here: https://lnkd.in/eKtHiGYS
-
-
Next week, we will announce our first quarter 2024 earnings and provide a corporate update. For more information, visit: https://lnkd.in/e9yzk9kC
-
-
We’re pleased to share that the U.S. FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation for TSHA-102 in Rett syndrome. This important milestone supports us on our mission to bring a potentially transformative #genetherapy to all patients and families living with #Rettsyndrome. Learn more: https://lnkd.in/gwvX3Dj3 #RMAT #RMATDesignation
-
-
Today, we announced our full-year 2023 earnings and provided updates on our TSHA-102 #genetherapy program in clinical evaluation for #Rettsyndrome, including the longer-term data from the first cohort in our REVEAL Phase 1/2 adolescent and adult trial. Learn more: https://lnkd.in/gwzAUnwA
-
Next week, we will announce our full-year 2023 earnings and provide corporate and clinical updates. For more information, visit: https://lnkd.in/dekHnCR7
Taysha Gene Therapies to Release Full-Year 2023 Financial Results, Provide Corporate and Clinical Updates and Host Conference Call on March 19 | Taysha Gene Therapies
ir.tayshagtx.com